Join our daily newsletter At The Bell to receive exclusive market insights
- Rhythm Biosciences (RHY) “successfully achieves” the end points for its clinical trial (study seven) of its ColoSTAT blood test
- ColoSTAT is a simple, low-cost blood test for detecting colorectal cancer that has the potential to ultimately provide an alternative to a colonoscopy
- The company says the trial “confirmed” ColoSTAT exhibited a very high accuracy for the detection of colorectal cancer, recording 81 per cent sensitivity and 91 per cent specificity
- Rhythm says ColoSTAT was shown to be 35 per cent more accurate than the market standard faecal immunochemical test (FIT) for detecting cancer and more accurate than FIT for detecting advanced adenomas
- RHY shares 10.2 per cent higher at $1.62
Rhythm Biosciences (RHY) has met the end points for its clinical trial (study seven) of its ColoSTAT blood test.
ColoSTAT is a simple, low-cost blood test for detecting colorectal cancer that has the potential to ultimately provide an alternative to a colonoscopy.
The company said the trial “confirmed” ColoSTAT exhibited a very high accuracy for the detection of colorectal cancer, recording 81 per cent sensitivity and 91 per cent specificity.
Rhythm said ColoSTAT was shown to be 35 per cent more accurate than the market standard faecal immunochemical test (FIT) for detecting cancer and more accurate than FIT for detecting advanced adenomas.
“We are extremely pleased with the significant positive outcomes from this study,” Managing Director and CEO Glenn Gilbert said.
“It further supports our conviction that ColoSTAT has the potential to transform the way colorectal cancer is detected, on a global scale.
“To achieve such a strong overall performance result and further, the meaningful
clinical significance versus the current market standard, FIT, further strengthens Rhythm’s position for significant positive outcomes moving forward, both economically and socially.”
Final submission of documentation for approval to the Therapeutic Goods Administration (TGA) remained on track for the first half of CY22, the company said.
RHY shares were trading 10.2 per cent higher at $1.62 at 2:32 pm AEST.
